Bausch + Lomb and IBM announced a collaboration to develop the first app of its kind for iPhone and iPad for surgeons who perform cataract surgery.
New Orleans-Bausch + Lomb and IBM announced a collaboration to develop the first app of its kind for iPhone and iPad for surgeons who perform cataract surgery.
The new app will help surgeons streamline their workflow by delivering patient information and clinical insights as well as IOL options on a single, digital platform at the point of care, said the companies in a prepared statement.
The app will be designed to electronically manage patient data across iPhone and iPad while hosting health-related data on the IBM Cloud Platform, Bluemix, and relaying customized IOL options to surgeons that they will use to help enhance surgical planning and provide better patient care.
By compiling each cataract patient’s information in the app-including IOL calculations, corneal topography, and other biometry results, as well as lifestyle preferences-surgeons and their staff may generate a comprehensive, integrated profile to help them facilitate IOL selection and procedure planning. Historical surgical data and other patient insights can also be housed within the app to potentially support positive clinical outcomes for future cataract.
“Bausch + Lomb is excited to collaborate with IBM to develop this innovative platform for ophthalmology,” said Andy Chang, senior vice president and general manager, U.S. Surgical, Bausch + Lomb. The collaboration will “provide surgeons with a convenient, personalized tool that helps them better manage and access patient profiles digitally, and provide personalized IOL options.”
“We look forward to bringing the benefits of mobile technology to some of the world’s busiest surgeons-cataract surgeons,” said Mahmoud Nagshineh, general manager, Apple partnership, IBM. “Bausch + Lomb has identified a significant need in the ophthalmic community and the new app we will create will equip ophthalmologists with the data they need at their fingertips to help them make better, more informed decisions for their patients.”
Pilot study testing for the new application is expected to begin in late 2016.